Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia

American Journal of Blood Research

Jean-François Viallard¹  Olivier Fain²  Hervé Maisonneuve³  Eric Jourdan⁴  Borhane Slama⁵ 

[1] Department of Internal Me;Department of Internal Medicine；Jean Verdier Hospital；France;Department of Internal Medicine；Les Oudairies Hospital；France;Hematology Department；Carémeau Hospital；France;Department of Haematology；Henri Duffaut Hospital；France

关键词: Acute myeloid leukemia;    elderly patients;    chemotherapy;    co-morbidities;    hypomethylating agents;    cytogenetics;    hematopoietic stem cell transplantation;   

学科分类：血液学

来源: e-Century Publishing Corporation

【 摘 要 】

Purpose: The present study was designed to assess the efficacy and safety of IGNG that is a new liquid, saccharose and maltose-free highly purified ready-to-use 5% intravenous immunoglobulin (IVIg), in primary immune thrombocytopenic patients with severe

【 授权许可】

CC BY-NC